30,450 Shares in Enzymotec Ltd (ENZY) Purchased by Gamco Investors INC. ET AL
Gamco Investors INC. ET AL purchased a new position in shares of Enzymotec Ltd (NASDAQ:ENZY) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 30,450 shares of the biotechnology company’s stock, valued at approximately $361,000.
Other large investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. acquired a new position in Enzymotec during the third quarter worth $107,000. SG Americas Securities LLC purchased a new stake in shares of Enzymotec during the fourth quarter worth $116,000. Osborn Williams & Donohoe LLC purchased a new stake in shares of Enzymotec during the third quarter worth $137,000. State Street Corp increased its position in shares of Enzymotec by 1.8% during the second quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock worth $169,000 after acquiring an additional 380 shares during the period. Finally, GABELLI & Co INVESTMENT ADVISERS INC. purchased a new stake in shares of Enzymotec during the fourth quarter worth $2,270,000. Institutional investors own 15.73% of the company’s stock.
Shares of Enzymotec Ltd (ENZY) opened at $11.85 on Wednesday. Enzymotec Ltd has a 12-month low of $6.30 and a 12-month high of $12.35. The firm has a market capitalization of $277.62, a price-to-earnings ratio of -43.89, a PEG ratio of 3.19 and a beta of 1.22.
A number of analysts have recently weighed in on ENZY shares. Wells Fargo & Co upped their price objective on Enzymotec from $9.50 to $12.00 and gave the stock a “market perform” rating in a research report on Monday, October 30th. Jefferies Group reaffirmed a “hold” rating and set a $11.50 price objective on shares of Enzymotec in a research report on Thursday, October 19th. BidaskClub lowered Enzymotec from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. Finally, Zacks Investment Research raised Enzymotec from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 17th. One analyst has rated the stock with a sell rating and four have assigned a hold rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $11.75.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Want to see what other hedge funds are holding ENZY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzymotec Ltd (NASDAQ:ENZY).
Receive News & Ratings for Enzymotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec and related companies with MarketBeat.com's FREE daily email newsletter.